kgi-admin

ITM-91 by ITM Isotope Technologies Munich for Metastatic Colorectal Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR […]

ITM-91 by ITM Isotope Technologies Munich for Metastatic Colorectal Cancer: Likelihood of Approval Read More »

Bendamustine hydrochloride by Mecox Cure Med for Unspecified B-Cell Lymphomas: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR

Bendamustine hydrochloride by Mecox Cure Med for Unspecified B-Cell Lymphomas: Likelihood of Approval Read More »

CSB-001 by Claris Biotherapeutics for Unspecified Ophthalmological Disorders: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR

CSB-001 by Claris Biotherapeutics for Unspecified Ophthalmological Disorders: Likelihood of Approval Read More »

Docetaxel + ritonavir by Modra Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR

Docetaxel + ritonavir by Modra Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval Read More »